" At $1,000 per test, that creates a potential $3.0 billion opportunity for LymPro once final commercial approval is granted. Under CLIA, the opportunity looks to be at least $100 million."
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links
